WEST LEBANON, N.H., Feb. 10, 2016 /PRNewswire/ -- Novo Nordisk showcased a multi-million dollar investment with diplomatic delegations from Denmark and the United States today, showing the company's commitment to maintaining a site in this rural community while ensuring a future medicines supply for serious disease like hemophilia and growth disorders.
Danish Ambassador to the United States Lars Gert Lose and U.S. Ambassador to Denmark Rufus Gifford toured the 170,000 square foot facility with Novo Nordisk U.S. President Jesper Hoiland. The site was acquired by Novo Nordisk in 2014, saving more than 100 manufacturing jobs and creating more than 300 new construction jobs for the local economy. Novo Nordisk plans to have a workforce of 150 people by the end of 2016.
"Denmark and the United States have a unique relationship, and we're proud, as one of Denmark's largest companies, to be expanding our presence in this country," said Henrik Wulff, executive vice president, product supply. "We're glad that we can call West Lebanon home, and increase our manufacturing capacity. Patients rely on us to make quality medicines that give them control over their diseases, and this site demonstrates our commitment to them."
The facility will produce medicines for the treatment of hemophilia, including the long-acting recombinant factor VIII, N8-GP for those with hemophilia A. It also recently made the decision to expand its ability to manufacture human growth hormone for a leading treatment used for children with growth disorders and adults who did not make enough growth hormones when younger.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: rare bleeding disorders, growth hormone-related disorders, and obesity. For more information, visit www.novonordisk.us or follow us on Twitter: @NovoNordiskUS.
SOURCE Novo Nordisk